Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals.
· 9/4/2026, 9:33:13 AM· 2 min read
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals.
Read original story →Related stories
business
Sensex rebounds 362 points, snaps 4-day losses on strong rally in metal, oil shares
business
Rupee rises 2 paise to close at 94.49 against U.S. dollar
business
Stock up on food to prepare for extreme weather, minister warns
business